CADTH Canadian Drug Expert Committee recommendation. indication : chronic hepatitis C virus infection. Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) :
The CADTH Canadian Drug Expert Committee (CDEC) recommends that glecaprevir/pibrentasvir (GP) be reimbursed for the treatment of adult patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis, including patients with HCV genotype 1 infection who were previously...
Saved in:
Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK533338/ Full text |
---|---|
Corporate Author: | |
Format: | Electronic eBook |
Language: | English |
Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
Edition: | Version 1.0. |
Series: | Common drug review clinical review report.
|
Subjects: |
Search Result 1
Search Result 2
Full text
Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation).
Published 2018
Get full text
Full text
Electronic
eBook
Search Result 3
Full text
Pharmacoeconomic review report. Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation).
Published 2018
Get full text
Full text
Electronic
eBook